21.87 USD
▲-0.14+8.43%
盘后 19.99 -0.89%
2026-08-03
市值
$2.43B
市盈率
—
EPS
-1.49
股息率
—
52 周区间
7.48 – 20.94
成交量
3.43M
Beta
-0.20
目标价
25.56
52W 低 7.4852W 高 20.94
价格走势
公司简介
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas...